Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732888 | 0.88 | DGAT1 (0.73) | DGAT1ROCK2PIM1PIM3SCN9A | |
| SCHEMBL14136848 | 0.86 | DGAT1 (0.59) | DGAT1ROCK2PIM1PIM3HPGD | |
| SCHEMBL14136900 | 0.81 | DGAT1 (0.59) | DGAT1SCN9AMCHR1 | |
| SCHEMBL23739883 | 0.78 | DGAT1 (0.63) | DGAT1 | |
| SCHEMBL15742442 | 0.77 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL15522458 | 0.76 | DGAT1 (0.82) | DGAT1ROCK2PIM1PIM3 | |
| SCHEMBL14137039 | 0.75 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL15733008 | 0.75 | DGAT1 (0.49) | DGAT1EGFRERBB2 | |
| SCHEMBL15733018 | 0.74 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL14136659 | 0.74 | DGAT1 (0.56) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3492474-B1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492474-A1 | INTERMEDIATES USED IN THE PRODUCTION OF DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2017-03-23 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2922551-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081994-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081994-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081342-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ROCK2 4661/4885PIM1 3739/4885 |
| US-10385066-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885ROCK2 1853/4885PIM1 1681/4885 |
| US-20140148437-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ROCK2 4661/4885PIM1 3739/4885 |
| US-20150322082-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885ROCK2 4661/4885PIM1 3739/4885 |
| US-20190135829-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | DGAT1 1/4885ROCK2 2144/4885PIM1 1484/4885 |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885ROCK2 1853/4885PIM1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.